Kuleon Bioscience

Kuleon Bioscience is a private, pre-clinical stage biotech founded in 2021 and headquartered in Seattle, Washington, with a focus on neuropsychiatric therapeutics. The company combines deep expertise in small molecule design with an AI-powered drug discovery engine to rapidly identify and patent novel compounds targeting the serotonergic system. Its pipeline is led by programs for substance use disorders (alcohol and drug abuse) currently in IND-enabling studies, supported by a broad intellectual property estate covering millions of novel molecules. Kuleon operates with a hybrid business model, pursuing both in-house development and out-licensing opportunities for its discovered assets.

Proprietary AI-based drug discovery engine combined with deep expertise in small molecule design, focused on selective modulation of serotonin receptor subtypes in the prefrontal cortex.

Kuleon competes in a crowded neuropsychiatric drug development landscape against large pharmaceutical companies, specialized biotechs, and a growing number of companies focused on psychedelic-derived and serotonin-targeting therapies. Its differentiation hinges on the precision of its receptor subtype targeting and the efficiency of its AI-powered discovery platform.